Backtest 308 evaluates a long-only, daily-bar systematic strategy on a universe of 1,006 world major-index constituents — now including KOSPI 50 (Korea) large caps — from 8 February 2016 to 30 April 2026 (≈ 10 years 3 months). Over that window the strategy compounds to a CAGR of 32.7% versus the S&P 500 total-return benchmark at 14.2%, with a max drawdown of -14.36% against the benchmark’s -33.92%. This run also re-bases the accounting currency from CHF to USD.

This is a historical backtest, not a live track record and not a trading signal. Past performance is not indicative of future results. Content is published for informational and educational purposes only — see the closing notes and our community page for the full disclaimer.

Headline numbers

MetricStrategyBenchmark (SPX TR)
Period2016-02-08 → 2026-04-30
CAGR32.72%14.19%
Cumulative return+1,712%+289%
Max drawdown-14.36%-33.92%
Longest DD (days)371745
Volatility (annualised)19.40%17.94%
Sharpe0.890.10
Sortino1.300.14
Calmar2.280.42
Time in market95%97%
Beta to SPX0.24
Trades966
Win rate49.48%
Risk / reward1.71
Skew-0.26-0.38
Kurtosis7.2816.64
QuantStats KPI snapshot over the matched window. The report sets the risk-free rate high (13.9%), which compresses the absolute Sharpe figure; an RF-flat internal computation gives a Sharpe of 0.96, Sortino 1.08 and Calmar 2.26 over the same window.

What changed since backtest 265

This report follows our previous world-indices study, Backtest 265. Two things changed on the data side:

  • Universe expanded with KOSPI 50. The major-indices zone now carries Korean large-cap constituents, taking the symbol count to 1,006. A broader cross-section gives the ranking logic more candidates per bar, but it also means this is not an apples-to-apples re-run of 265 — the opportunity set is different.
  • Base currency switched CHF → USD. The portfolio is now denominated, financed and reported in USD. This is primarily an accounting / FX-translation change (cash, borrow accrual and the equity curve are all in USD); it is not a change to the entry or exit logic. Read the headline CAGR with that in mind — part of any difference versus 265 is FX and universe, not signal alpha.

The entry/exit rules in this run (MACD-variant entry, Ichimoku + Parabolic-SAR exit — see below) also differ from 265’s configuration, so treat 308 as its own backtest rather than a like-for-like delta on 265.

Universe & period

The universe is the major-indices zone — 1,006 constituents of large world indices (now including KOSPI 50), daily bars, denominated in USD. The simulation warms up indicators from 2014-12-19 and starts compounding from 2016-02-08 with $100,000 of initial capital, ending 2026-04-30.

Strategy in plain English

  • Long-only, no shorts, no leverage (gross exposure averages ~50%).
  • Entry: a MACD-variant trigger (internally macdv1b).
  • Exit: a composite of Ichimoku and Parabolic-SAR rules (internally ichimoku6a + psar0a), combined with a 28% trailing stop.
  • Sizing: volatility-targeted at the portfolio level, position cap 20%, sector cap 33%, max 10 new entries per bar.
  • Cooldown: a freeze of 2 bars after each exit to avoid immediate re-entries.
  • Regime awareness: a 252-bar percentile-based regime filter. Over the test window bars classify as ~78% trend, ~8% range, ~15% bear (see our follow-up null-result study on whether this filter actually improves backtest outcomes) — the strategy is permitted in all three but sizes down outside trend.

Equity curve

Backtest 308 — cumulative returns vs SPX benchmark (linear scale)
Cumulative returns vs SPX. Linear scale.
Backtest 308 — cumulative returns, log scale
Same curve, log scale — early compounding is easier to read.

Annual returns

YearSPXStrategyMultiplierWon
201619.08%11.75%0.62
201719.42%13.44%0.69
2018-6.24%13.02%-2.09+
201928.88%29.80%1.03+
202016.26%81.06%4.99+
202126.89%46.70%1.74+
2022-19.44%7.91%-0.41+
202324.23%18.99%0.78
202423.31%37.60%1.61+
202516.39%79.72%4.86+
2026*5.31%15.54%2.93+
Calendar-year returns vs SPX. The strategy beats the benchmark in 8 of 11 years; 2022 (SPX -19.44% / Strategy +7.91% — positive in a down market) is the standout. *2026 is a partial year through 30 April.
Backtest 308 — end-of-year returns vs benchmark
EOY returns — strategy bars vs benchmark. The dashed line marks the strategy’s average annual return.

Drawdown analysis

The deepest drawdown sits at -14.36%, spanning the COVID window (Dec 2019 – Jun 2020). No single drawdown in the record exceeds -15%, and the strategy spends most of its time within a few percent of its high-water mark — versus -33.92% peak-to-trough for SPX over the same window. Note the third-worst drawdown (-13.64%, starting 2026-02-13) was still open at the end of the sample on 30 April 2026; its “recovered” date is simply the last bar, not a true recovery.

Backtest 308 — worst 5 drawdown periods
Equity curve with the worst five drawdown windows shaded.
Backtest 308 — underwater (drawdown) plot
Underwater plot — time spent below previous peak. The dashed line is the average drawdown (-3.15%).
StartedRecoveredDrawdownDays
2019-12-062020-06-03-14.36%181
2021-02-172021-07-29-13.66%163
2026-02-13(open)-13.64%77
2024-07-172024-09-18-13.13%64
2020-08-072020-08-28-11.74%22
2020-11-172020-12-02-11.49%16
2020-09-032020-11-06-10.79%65
2017-11-222018-01-11-10.76%51
2024-09-302025-03-14-9.89%166
2021-01-262021-02-11-9.77%17
Worst 10 drawdowns by depth. The 2026-02-13 episode was unrecovered at the sample’s end.

Rolling metrics

Backtest 308 — 6-month rolling volatility
6-month rolling volatility (annualised). The strategy and SPX trade places depending on regime; on average both sit near 18–19%.
Backtest 308 — 6-month rolling Sharpe
6-month rolling Sharpe — repeated swings above and below the long-run average rather than a single persistent regime.
Backtest 308 — 6-month rolling beta vs SPX
Rolling beta vs SPX — low on average (full-sample beta 0.24) but cycling between ~0 and ~0.9 as net exposure shifts.

Return distribution

Backtest 308 — monthly returns heatmap
Monthly returns heatmap. Negative months are common but shallow; the outsized months (Jul 2020 +29.1%, Aug 2021 +17.8%, Oct 2025 +18.3%) carry the compounding.
Backtest 308 — distribution of monthly returns
Distribution of monthly returns versus SPX — a fatter right tail and the occasional large up-month.
Backtest 308 — return quantiles
Return quantiles across daily, weekly, monthly, quarterly and yearly horizons.

Caveats & reading guide

  • This is a backtest, not a live track record. Trades are simulated on historical daily bars; real-world execution would face additional slippage, partial fills, and venue-specific frictions.
  • Universe changed mid-lineage. Adding KOSPI 50 means the cross-section differs from earlier world-indices runs; do not read the CAGR as a clean improvement over 265.
  • Base-currency / FX. Results are in USD. The CHF → USD switch moves cash, borrow accrual and the reported equity curve into USD and therefore embeds USD/foreign FX moves into the headline numbers.
  • Survivorship. The universe is built from current and historical major-index constituents; while care is taken to include delisted names, residual survivorship bias cannot be ruled out.
  • Risk-free rate. The QuantStats report uses a high annual RF (13.9%, inherited from a working assumption), which mechanically suppresses the printed Sharpe. An RF-flat internal calculation reports Sharpe 0.96, Sortino 1.08 and Calmar 2.26 over the same window.
  • Costs. Transaction costs, a value-traded borrow-fee model (0.8%) and a 1.5% margin spread are modelled at the bar level; the strategy turns over ~95 trades per year on average (966 total).
  • Out-of-sample. Parameter selection used the early portion of the window; results from 2020 onward give a more honest read of out-of-sample behaviour. The open -13.6% drawdown into April 2026 is a reminder that recent bars are not yet resolved. Hard cutoff: the strategy’s rules and parameters were frozen on 3 July 2025, so all performance after that date is genuine out-of-sample / forward-tracked data — unseen at selection time, with no hindsight possible.

Discuss this backtest

We share backtest research, methodology notes and discussion on our free community channels — Telegram, Discord, X. Full details and the bilingual disclaimer on the community page.

KreamEdge publishes systematic strategy backtests and market analytics for informational and educational purposes only — not personalised investment advice. Past performance is not indicative of future results.


0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *